Regeneron Pharmaceuticals, Inc.
REGN
NASDAQ·Healthcare·Biotechnology·Mkt cap $85.3B
$827.72
▼ -1.87%
P/E
20.28
Mkt Cap
$85.3B
52-Wk Range
$541.00–$859.34
52-Week Range
$541.00 - $859.34
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 48.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Advanced proprietary antibody technologies
- Extensive research and development capabilities
- Strategic pharmaceutical partnerships
- Diversified therapeutic portfolio
Bear Case
1 risk
- Low volatility (beta 0.2).
Growth
Stable outlook
Continued innovation in biologics
Value
Undervalued - trading well below Biotech & Therapeutics peers
Momentum
Hot
+35.4% over 3m
Quality
Excellent
Excellent business quality
Dividend
Token
0.45% yield
Smart-money signal
Who's buying REGN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 27, 2026
JUL 30, 2026
Reported EPS of $14.29 vs $10.16 consensus (+40.6% surprise). Revenue of $4.3B vs $3.8B expected (+12.4%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+40.6%
Revenue trend · last 8Q
—
+10%
-4%
+4%
+1%
+3%
+19%
+17%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$3.7B
$3.8B
$3.0B
$3.7B
$3.8B
$3.9B
$3.6B
$4.3B
Margins · last 8Q
Gross
98.3%
Operating
30.1%
Profit
30.2%
Wall Street consensus
15 analysts · 60% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
60%
Hold
40%
Sell
0%
Median Price Target
—
Latest: Bernstein · Aug 14, 2026
vs Industry
How REGN stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related